214 related articles for article (PubMed ID: 36788102)
41. Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated.
Raj N; Valentino E; Capanu M; Tang LH; Basturk O; Untch BR; Allen PJ; Klimstra DS; Reidy-Lagunes D
Pancreas; 2017 Mar; 46(3):296-301. PubMed ID: 27759713
[TBL] [Abstract][Full Text] [Related]
42. Exploratory genomic analysis of high-grade neuroendocrine neoplasms across diverse primary sites.
Sun TY; Zhao L; Van Hummelen P; Martin B; Hornbacker K; Lee H; Xia LC; Padda SK; Ji HP; Kunz P
Endocr Relat Cancer; 2022 Dec; 29(12):665-679. PubMed ID: 36165930
[TBL] [Abstract][Full Text] [Related]
43. Performance of DAXX Immunohistochemistry as a Screen for DAXX Mutations in Pancreatic Neuroendocrine Tumors.
Hechtman JF; Klimstra DS; Nanjangud G; Frosina D; Shia J; Jungbluth AA
Pancreas; 2019 Mar; 48(3):396-399. PubMed ID: 30747827
[TBL] [Abstract][Full Text] [Related]
44. Rb Loss and
Hijioka S; Hosoda W; Matsuo K; Ueno M; Furukawa M; Yoshitomi H; Kobayashi N; Ikeda M; Ito T; Nakamori S; Ishii H; Kodama Y; Morizane C; Okusaka T; Yanagimoto H; Notohara K; Taguchi H; Kitano M; Yane K; Maguchi H; Tsuchiya Y; Komoto I; Tanaka H; Tsuji A; Hashigo S; Kawaguchi Y; Mine T; Kanno A; Murohisa G; Miyabe K; Takagi T; Matayoshi N; Yoshida T; Hara K; Imamura M; Furuse J; Yatabe Y; Mizuno N
Clin Cancer Res; 2017 Aug; 23(16):4625-4632. PubMed ID: 28455360
[No Abstract] [Full Text] [Related]
45. Non-Ductal Tumors of the Pancreas.
Dhillon J
Monogr Clin Cytol; 2020; 26():92-108. PubMed ID: 32987393
[TBL] [Abstract][Full Text] [Related]
46. An analysis of 130 neuroendocrine tumors G3 regarding prevalence, origin, metastasis, and diagnostic features.
Kasajima A; Konukiewitz B; Schlitter AM; Weichert W; Klöppel G
Virchows Arch; 2022 Feb; 480(2):359-368. PubMed ID: 34499237
[TBL] [Abstract][Full Text] [Related]
47. Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review.
Girardi DM; Silva ACB; Rêgo JFM; Coudry RA; Riechelmann RP
Cancer Treat Rev; 2017 May; 56():28-35. PubMed ID: 28456055
[TBL] [Abstract][Full Text] [Related]
48. Pancreatic neuroendocrine neoplasms: Updates on genomic changes in inherited tumour syndromes and sporadic tumours based on WHO classification.
Ishida H; Lam AK
Crit Rev Oncol Hematol; 2022 Apr; 172():103648. PubMed ID: 35248713
[TBL] [Abstract][Full Text] [Related]
49. Gene expression profiling of pancreatic neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm.
Kinowaki Y; Fukumura Y; Kawade G; Sugita K; Kinowaki K; Akahoshi K; Kobayashi M; Ono H; Kudo A; Tanabe M; Akashi T; Ohashi K; Kurata M
Gene; 2024 Jan; 893():147916. PubMed ID: 37866661
[TBL] [Abstract][Full Text] [Related]
50. Molecular profile of pancreatic neuroendocrine neoplasms (PanNENs): Opportunities for personalized therapies.
Arakelyan J; Zohrabyan D; Philip PA
Cancer; 2021 Feb; 127(3):345-353. PubMed ID: 33270905
[TBL] [Abstract][Full Text] [Related]
51. Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors.
Uemura J; Okano K; Oshima M; Suto H; Ando Y; Kumamoto K; Kadota K; Ichihara S; Kokudo Y; Maeba T; Nanno Y; Toyama H; Takada Y; Shimada M; Hanazaki K; Masaki T; Suzuki Y
Ann Surg; 2021 Dec; 274(6):e949-e956. PubMed ID: 31599805
[TBL] [Abstract][Full Text] [Related]
52. Immunohistochemical analysis of OTP and NKX6.1 in neuroendocrine tumors of the lung and pancreas.
Yoxtheimer LM; Heymann JJ; Cohen C; Rao RA; Goyal A; Siddiqui MT
Diagn Cytopathol; 2018 Dec; 46(12):1010-1014. PubMed ID: 30284410
[TBL] [Abstract][Full Text] [Related]
53. Molecular subtyping in pancreatic neuroendocrine neoplasms: New insights into clinical, pathological unmet needs and challenges.
Yan J; Yu S; Jia C; Li M; Chen J
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188367. PubMed ID: 32339609
[TBL] [Abstract][Full Text] [Related]
54. Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites.
Uccella S; La Rosa S; Metovic J; Marchiori D; Scoazec JY; Volante M; Mete O; Papotti M
Endocr Pathol; 2021 Mar; 32(1):192-210. PubMed ID: 33433884
[TBL] [Abstract][Full Text] [Related]
55. Prognostic Significance of Altered ATRX/DAXX Gene in Pancreatic Neuroendocrine Tumors: A Meta-Analysis.
Wang F; Xu X; Ye Z; Qin Y; Yu X; Ji S
Front Endocrinol (Lausanne); 2021; 12():691557. PubMed ID: 34220718
[TBL] [Abstract][Full Text] [Related]
56. Pancreatic Neuroendocrine Neoplasms: Landscape and Horizon.
Tang LH
Arch Pathol Lab Med; 2020 Jul; 144(7):816-828. PubMed ID: 32298138
[TBL] [Abstract][Full Text] [Related]
57. Gastric mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) with pancreatic acinar differentiation: a case report.
Fujita Y; Uesugi N; Sugimoto R; Eizuka M; Matsumoto T; Sugai T
Diagn Pathol; 2019 May; 14(1):38. PubMed ID: 31077220
[TBL] [Abstract][Full Text] [Related]
58. Treatment landscape of advanced high-grade neuroendocrine neoplasms.
Alheraki SZ; Almquist DR; Starr JS; Halfdanarson TR; Sonbol MB
Clin Adv Hematol Oncol; 2023 Jan; 21(1):16-26. PubMed ID: 36638352
[TBL] [Abstract][Full Text] [Related]
59. Genetic alterations of GI-NECs involving three main signaling pathways.
Dai Q; Zhang J; Long W; Haybaeck J; Yang Z
Cancer Med; 2023 Apr; 12(7):8238-8250. PubMed ID: 36653904
[TBL] [Abstract][Full Text] [Related]
60. A Subset of Large Cell Neuroendocrine Carcinomas in the Gastroenteropancreatic Tract May Evolve from Pre-existing Well-Differentiated Neuroendocrine Tumors.
Pelosi G; Bianchi F; Dama E; Metovic J; Barella M; Sonzogni A; Albini A; Papotti M; Gong Y; Vijayvergia N
Endocr Pathol; 2021 Sep; 32(3):396-407. PubMed ID: 33433886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
